Literature DB >> 10363572

Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study.

K Tanaka1, M Ikeda, A Nozaki, N Kato, H Tsuda, S Saito, H Sekihara.   

Abstract

Hepatitis C virus (HCV) is associated with the development of cirrhosis and hepatocellular carcinoma. We recently found that bovine lactoferrin, a milk protein belonging to the iron transporter family, effectively prevented HCV infection in cultured human hepatocytes (PH5CH8). We tested the hypothesis that lactoferrin inhibits HCV viremia in patients with chronic hepatitis C. Eleven patients with chronic hepatitis C received an 8-week course of bovine lactoferrin (1.8 or 3.6 g/day). At the end of lactoferrin treatment, a decrease in serum alanine transaminase and HCV RNA concentrations was apparent in 3 (75%) of 4 patients with low pretreatment serum concentrations of HCV RNA. However, 7 patients with high pretreatment concentrations showed no significant changes in these indices. This pilot study suggests that lactoferrin is one potential candidate as an anti-HCV reagent that may be effective for the treatment of patients with chronic hepatitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10363572      PMCID: PMC5926088          DOI: 10.1111/j.1349-7006.1999.tb00756.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  25 in total

1.  Analysis of the cell tropism of HCV by using in vitro HCV-infected human lymphocytes and hepatocytes.

Authors:  M Ikeda; N Kato; T Mizutani; K Sugiyama; K Tanaka; K Shimotohno
Journal:  J Hepatol       Date:  1997-09       Impact factor: 25.083

Review 2.  Lactoferrin: a general review.

Authors:  P F Levay; M Viljoen
Journal:  Haematologica       Date:  1995 May-Jun       Impact factor: 9.941

3.  Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes.

Authors:  M Ikeda; K Sugiyama; T Tanaka; K Tanaka; H Sekihara; K Shimotohno; N Kato
Journal:  Biochem Biophys Res Commun       Date:  1998-04-17       Impact factor: 3.575

4.  Hepatic and extrahepatic HCV RNA strands in chronic hepatitis C: different patterns of response to interferon treatment.

Authors:  B Gil; C Qian; J I Riezu-Boj; M P Civeira; J Prieto
Journal:  Hepatology       Date:  1993-11       Impact factor: 17.425

5.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.

Authors:  Y Shiratori; N Kato; O Yokosuka; F Imazeki; E Hashimoto; N Hayashi; A Nakamura; M Asada; H Kuroda; N Tanaka; Y Arakawa; M Omata
Journal:  Gastroenterology       Date:  1997-08       Impact factor: 22.682

7.  Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus.

Authors:  M Ikeda; K Sugiyama; T Mizutani; T Tanaka; K Tanaka; H Sekihara; K Shimotohno; N Kato
Journal:  Virus Res       Date:  1998-08       Impact factor: 3.303

8.  Inhibition with lactoferrin of in vitro infection with human herpes virus.

Authors:  K Hasegawa; W Motsuchi; S Tanaka; S Dosako
Journal:  Jpn J Med Sci Biol       Date:  1994-04

9.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

10.  Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro.

Authors:  M C Harmsen; P J Swart; M P de Béthune; R Pauwels; E De Clercq; T H The; D K Meijer
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

View more
  22 in total

1.  Bovine lactoferrin induces interleukin-11 production in a hepatitis mouse model and human intestinal myofibroblasts.

Authors:  Tetsuya Kuhara; Koji Yamauchi; Keiji Iwatsuki
Journal:  Eur J Nutr       Date:  2011-06-19       Impact factor: 5.614

2.  Enteral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates.

Authors:  Mohan Pammi; Steven A Abrams
Journal:  Cochrane Database Syst Rev       Date:  2019-05-11

Review 3.  Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants.

Authors:  Mohan Pammi; Gautham Suresh
Journal:  Cochrane Database Syst Rev       Date:  2017-06-28

4.  Inhibition of HBV infection by bovine lactoferrin and iron-, zinc-saturated lactoferrin.

Authors:  Songtao Li; Haibo Zhou; Guirong Huang; Ning Liu
Journal:  Med Microbiol Immunol       Date:  2008-09-23       Impact factor: 3.402

Review 5.  Manipulation of iron to determine survival: competition between host and pathogen.

Authors:  Nihay Laham; Rachel Ehrlich
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  Relationship of Oxidative Stress with HIV Disease Progression in HIV/HCV Co-infected and HIV Mono-infected Adults in Miami.

Authors:  Dong-Ho Shin; Sabrina S Martinez; Mary Parsons; Dushyantha T Jayaweera; Adriana Campa; Marianna K Baum
Journal:  Int J Biosci Biochem Bioinforma       Date:  2012

7.  Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin.

Authors:  Hiroyuki Wakabayashi; Natsuko Takakura; Koji Yamauchi; Yoshitaka Tamura
Journal:  Clin Vaccine Immunol       Date:  2006-02

8.  Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection.

Authors:  Jose Azocar; Arley Diaz
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

9.  Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants.

Authors:  Mohan Pammi; Gautham Suresh
Journal:  Cochrane Database Syst Rev       Date:  2020-03-31

10.  Lactoferrin Against SARS-CoV-2: In Vitro and In Silico Evidences.

Authors:  Elena Campione; Caterina Lanna; Terenzio Cosio; Luigi Rosa; Maria Pia Conte; Federico Iacovelli; Alice Romeo; Mattia Falconi; Claudia Del Vecchio; Elisa Franchin; Maria Stella Lia; Marilena Minieri; Carlo Chiaramonte; Marco Ciotti; Marzia Nuccetelli; Alessandro Terrinoni; Ilaria Iannuzzi; Luca Coppeda; Andrea Magrini; Sergio Bernardini; Stefano Sabatini; Felice Rosapepe; Pier Luigi Bartoletti; Nicola Moricca; Andrea Di Lorenzo; Massimo Andreoni; Loredana Sarmati; Alessandro Miani; Prisco Piscitelli; Piera Valenti; Luca Bianchi
Journal:  Front Pharmacol       Date:  2021-06-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.